Catalyst Pharmaceutical

CPRX

Market cap $2.94B

Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript

CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance.

The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMREE Franchises Promoted Product Revenue, Net Expected to Grow by 20% or More in 2026 Conference Call and Webcast to be Held on February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for fourth quarter and full year 2025 and provided full year 2026 financial guidance.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Catalyst (CPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.

CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, being held in Miami, Florida.

Catalyst Pharmaceuticals management asserts a $1B+ LEMS market opportunity, estimating 3,600–5,400 addressable patients, with growth driven by improved diagnosis and market penetration. Recent presentations highlight 15–20% continuous growth in LEMS, with strategic emphasis on both idiopathic and cancer-associated segments to expand FIRDAPSE's reach. In addition to LEMS, Catalyst controls North American rights to the DMD drug AGAMREE, which is enjoying significant growth.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.